Business
Quince Therapeutics Announces Topline Results from Pivotal Phase 3 NEAT Clinical Trial of eDSP in Ataxia-Telangiectasia
SOUTH SAN FRANCISCO, Calif., January 29, 2026--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today announced topline results from its pivotal Phase 3 NEAT clinical trial evaluating its lead asset, dexamethasone sodium phosphate encapsulated in autologous erythrocytes (eDSP), in patients with Ataxia-Telangiectasia (A-T).
About this update from Quince Therapeutics, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1121,"height":442,"url":"https://media.zenfs.com/en/business-wire.com/8989a20a7e8e7d4fab9f5e5f93957100"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/XbuaNQG8NtD6uTi0DQE.hA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTM3OTtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/8989a20a7e8e7d4fab9f5e5f93957100","width":960,"height":379},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/yeU7gF_lrf063wCoedKVvA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIyNDI7aD04ODQ7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/8989a20a7e8e7d4fab9f5e5f93957100","width":1121,"height":442}},"lazy":false},{"type":"text","content":"Primary and key secondary endpoint did not achieve statistical significance","length":75,"tagName":"p","attribs":{}},{"type":"text","content":"eDSP was generally well tolerated with no clinically meaningful safety concerns identified","length":90,"tagName":"p","attribs":{}},{"type":"text","content":"Company to cease clinical development of eDSP; Intends to preserve cash and explore available options","length":101,"tagName":"p","attribs":{}},{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., January 29, 2026--(BUSINESS WIRE)--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today announced topline results from its pivotal Phase 3 NEAT clinical trial evaluating its lead asset, dexamethasone sodium phosphate encapsulated in autologous erythrocytes (eDSP), in patients with Ataxia-Telangiectasia (A-T).","length":465,"tagName":"p"},{"type":"text","content":"In the NEAT study, the company’s pivotal Phase 3 international, multicenter, randomized, double-blind, placebo-controlled study (n=105), the primary endpoint, which measured the change from baseline to last efficacy visit at month six using the Rescored modified International Cooperative Ataxia Rating Scale (RmICARS) compared to placebo, did not reach statistical significance. The mean change from baseline to month six was 0.94 in the active arm compared to 2.24 in the placebo arm (difference -1.30) with a p-value of 0.0851. Furthermore, the study did not meet its key secondary endpoint of improvement in Clinical Global Impres...